Toll Free: 1-888-928-9744
Published: Oct, 2014 | Pages:
30 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Interprotein Corporation - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Interprotein Corporation - Product Pipeline Review - 2014', provides an overview of the Interprotein Corporation's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Interprotein Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Interprotein Corporation including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Interprotein Corporation's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Interprotein Corporation's pipeline products Reasons to buy - Evaluate Interprotein Corporation's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Interprotein Corporation in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Interprotein Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Interprotein Corporation and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Interprotein Corporation - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Interprotein Corporation and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Interprotein Corporation Snapshot 5 Interprotein Corporation Overview 5 Key Information 5 Key Facts 5 Interprotein Corporation - Research and Development Overview 6 Key Therapeutic Areas 6 Interprotein Corporation - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Partnered Products 11 Partnered Products/Combination Treatment Modalities 12 Pipeline Products - Out-Licensed Products 13 Out-Licensed Products/Combination Treatment Modalities 14 Interprotein Corporation - Pipeline Products Glance 15 Interprotein Corporation - Early Stage Pipeline Products 15 Preclinical Products/Combination Treatment Modalities 15 Discovery Products/Combination Treatment Modalities 16 Interprotein Corporation - Drug Profiles 17 IPC-003 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 IPZ-010 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 Small Molecule to Inhibit IL-6 for Autoimmune Disorders and Inflammation 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 Small Molecule to Inhibit VEGF for Oncology 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 Small Molecule to Inhibit IgE for Allergies 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Small Molecule to Inhibit Notch-1 for Oncology and Hematological Disorders 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 Interprotein Corporation - Pipeline Analysis 24 Interprotein Corporation - Pipeline Products by Target 24 Interprotein Corporation - Pipeline Products by Molecule Type 25 Interprotein Corporation - Pipeline Products by Mechanism of Action 26 Interprotein Corporation - Recent Pipeline Updates 27 Interprotein Corporation - Locations And Subsidiaries 28 Head Office 28 Other Locations & Subsidiaries 28 Appendix 29 Methodology 29 Coverage 29 Secondary Research 29 Primary Research 29 Expert Panel Validation 29 Contact Us 30 Disclaimer 30
List of Tables Interprotein Corporation, Key Information 5 Interprotein Corporation, Key Facts 5 Interprotein Corporation - Pipeline by Indication, 2014 8 Interprotein Corporation - Pipeline by Stage of Development, 2014 9 Interprotein Corporation - Monotherapy Products in Pipeline, 2014 10 Interprotein Corporation - Partnered Products in Pipeline, 2014 11 Interprotein Corporation - Partnered Products/ Combination Treatment Modalities, 2014 12 Interprotein Corporation - Out-Licensed Products in Pipeline, 2014 13 Interprotein Corporation - Out-Licensed Products/ Combination Treatment Modalities, 2014 14 Interprotein Corporation - Preclinical, 2014 15 Interprotein Corporation - Discovery, 2014 16 Interprotein Corporation - Pipeline by Target, 2014 24 Interprotein Corporation - Pipeline by Molecule Type, 2014 25 Interprotein Corporation - Pipeline Products by Mechanism of Action, 2014 26 Interprotein Corporation - Recent Pipeline Updates, 2014 27 Interprotein Corporation, Other Locations 28
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.